14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IONS vs PTGX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Protagonist Therapeutics, Inc (PTGX) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas PTGX carries 32.6/100 (SELL) at $125.40 (36.9x Forward P/E, 58.6% operating margin).
Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTGX 32.6/100 SELL), PTGX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (58.6% vs. -58.8% operating margin) and revenue trajectory (+5723.6% vs. +54.9% YoY).
Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile PTGX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment61.8% of Rev ($593M)
90D Engineering Disclosures0 Published
PTGX Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $8.7B market capitalization and 58.6% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($227M)
90D Engineering Disclosures0 Published
Investor FAQ IONS vs PTGX Key Questions & Quantitative Answers
As of Nov 16, 2026, Protagonist Therapeutics, Inc (PTGX) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas PTGX carries 32.6/100 (SELL) at $125.40 (36.9x Forward P/E, 58.6% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTGX 32.6/100 SELL), PTGX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (58.6% vs. -58.8% operating margin) and revenue trajectory (+5723.6% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile PTGX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PTGX leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with PTGX at +5723.6% YoY revenue growth and +351.3% YoY earnings growth on $552M TTM revenue (99.8% gross margin, 58.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while PTGX shifted +66.7%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($227M) (0 disclosures) for PTGX.
PTGX screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas PTGX trades at 36.9x Forward P/E, 28.1x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (19.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus PTGX (39.6% ROE) capital efficiency.
In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, PTGX carries 39.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.02β · 35% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.